Multiple tumor-associated antigens presented via HLA-A2

Class

HLA-A2-restricted, multi-neoepitope peptide cancer vaccine (10 peptides in Montanide ISA 51 adjuvant); INN Tedopi

Pathway

Neoepitope-specific CD8+ T-cell activation

Notes

original target text: Multiple tumor-associated antigens presented via HLA-A2 (incl. p53, HER2, MAGE2/3)

This mechanism describes a therapeutic cancer vaccine designed to teach the immune system to recognize and destroy tumor cells. Rather than targeting a single molecule, it presents multiple short protein fragments, called peptides, derived from tumor-associated antigens such as p53, HER2, and MAGE2/3 — proteins that are frequently overexpressed, mutated, or abnormally expressed in cancer cells. These peptides are formulated to bind specifically to HLA-A2, a common variant of human leukocyte antigen class I, the molecular display system cells use to show their internal protein contents to the immune system. When taken up by antigen-presenting cells and displayed on HLA-A2, the peptides activate CD8+ T cells, the immune cells responsible for directly killing abnormal cells. An oil-based adjuvant is included to enhance and prolong this immune stimulation. The rationale for combining several peptides rather than one is that tumors are genetically heterogeneous and can lose or downregulate individual antigens to escape immune detection; targeting multiple antigens simultaneously broadens the immune response and reduces the chance of complete escape. This class of mechanism is relevant across solid tumors that express these shared antigens, and reflects a broader strategy in oncology of harnessing adaptive immunity rather than directly poisoning cancer cells.